Page 1

SANOFI Paris , April 28 , 2021 Sanofi continued its growth trajectory . Strong increase in Q1 2021 business EPS ( 1 ) at CER . Q1 2021 sales increase of 2.4 % at CER driven by growth drivers DupixentⓇ and Vaccines • • • • Specialty Care sales grew 15.3 % , due to strong DupixentⓇ performance ( + 45.6 % to € 1,047 million ) and oncology launches Vaccines up 5.3 % , driven by PPH franchise and demand for influenza vaccines in southern hemisphere General Medicines core assets grew 4.4 % , while GBU sales were down 3.8 % CHC decreased 7.3 % due to COVID related stocking in Q1 2020 and low demand for cough and cold brands in Europe Q1 2021 business EPS ( 1 ) growth at CER driven by efficiency and sales performance , supported by a one - time payment • Business EPS ( 1 ) was € 1.61 up 5.2 % on a reported basis and up 15.0 % at CER • • Business EPS ( 1 ) includes an incremental 8 cents due to a payment related to the termination of a collaboration in Japan IFRS EPS was € 1.25 Progress on implementation of the Corporate Social Responsibility strategy • Sanofi has become a member of the top five companies of the 2021 Access to Medicine index • Sanofi announced Sanofi Global Health , a newly formed non - profit unit within the company , a new cornerstone of its CSR strategy Full - year 2021 business EPS guidance affirmed • Sanofi expects 2021 business EPS ( 1 ) to grow high single digit ( 2 ) at CER , barring unforeseen major adverse events . Applying average April 2021 exchange rates , the currency impact on 2021 business EPS is estimated to be between -4 % to -5 % . Sanofi Chief Executive Officer , Paul Hudson , commented : " Our strong first - quarter performance is the result of the continued execution of our Play to Win strategy to drive growth and bring innovative medicines to patients . DupixentⓇ continues its outstanding performance with impressive growth in the U.S. and strong uptake in global markets , including China . Vaccines delivered growth in its core segments . We initiated and completed enrollment of our Phase 2 study for our recombinant COVID - 19 vaccine candidate in the first quarter and results are expected next month . Following the communication of our ESG strategy at the end of 2020 and embedding it into our business priorities , we have recently created the Sanofi Global Health Unit , dedicated to increasing access to 30 medicines considered essential by the WHO . Sanofi is uniquely positioned to make this difference to society , which can be scaled and sustained over time , given our portfolio of essential medicines and broad geographic presence . " IFRS net sales reported IFRS net income reported IFRS EPS reported Free cash flow ( 3 ) Business operating income Business net income ( 1 ) Business EPS ( 1 ) Q1 2021 Change Change at CER € 8,591m -4.3 % + 2.4 % € 1,566m -7.0 % € 1.25 -7.4 % € 1,925m + 23.6 % € 2,638m + 4.0 % + 13.3 % € 2,017m + 5.1 % + 14.7 % € 1.61 + 5.2 % + 15.0 % Changes in net sales are expressed at constant exchange rates ( CER ) unless otherwise indicated ( definition in Appendix 7 ) ( 1 ) In order to facilitate an understanding of operational performance , Sanofi comments on the business net income statement . Business net income is a non - GAAP financial measure ( definition in Appendix 7 ) . The consolidated income statement for Q1 2021 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4 ; ( 2 ) 2020 restated business EPS was € 5.86 ; ( 3 ) Free cash flow is a non - GAAP financial measure ( definition in Appendix 7 ) .